## NPSA Medicines Shortages CSOD Supply Restriction under COVID-19 Working Group

## AGENDA 16

| Time \& Date: | $4 \mathrm{pm}-4.30 \mathrm{pm}$ Tuesday October $27 \mathrm{th}, 2020$ |
| :--- | :--- |
| Venue: | Teleconference |
| Host: |  |
| Attendees: | -NPSA Executive Director |
|  | Sigma Healthcare |
|  | API |
|  | Symbion |
|  | Symbion |
|  | Sigma Healthcare |
|  | National Pharmacies |


| 1 | Welcome - apologies <br> - Reminder of meeting purpose and conduct as per ACCC temporary authorisation <br> - Review of the previous minutes - refer to Attachment A | EC <br> ALL |
| :---: | :---: | :---: |
| 2 | Trends in supply and demand of medicines <br> - General discussion by all members on trends and observations over the previous week with focus on new spikes in cases | ALL |
| 3 | Specific medicines at risk - NEW <br> - General discussion by all members on any NEW medicines identified or have been placed on a watch list | ALL |
| 4 | Specific medicines at risk - EXISTING <br> - General discussion by all members on existing medicines placed on restriction - maintain or adjust - currently $\square$ $\square$ <br> Refer to Attachment B ACCC Update October 92020 | ALL |
| 5 | Reporting |  |


|  | - TGA Reporting protocol - <br> Refer to Attachment C - TGA Reporting Protocol - draft <br> - Update on ACCC Authorisation and associated reporting <br> - Update on Mask weekly report | ALL <br> EC <br> EC/ALL |
| :---: | :---: | :---: |
| 6. | Other Business |  |
|  | - Border closures - any impact on medicine supply <br> - COVID Vaccine Distribution update | $\begin{aligned} & \text { ALL } \\ & \mathrm{EC} \end{aligned}$ |

Attachment C-email from re draft output workbook



National Pharmaceutical

Annexure A

NPSA Medicines Shortages CSOD Supply Restriction under COVID-19 Working Group
Minutes 15


| ITEM | DISCUSSION AREA | ACTION AGREED |
| :---: | :---: | :---: |
| 1 | Welcome- <br> - Meeting purpose and conduct as per ACCC Authorisation was discussed and agreed. <br> - Minutes from September 15, 2020 meeting accepted. | Noted <br> Minutes Accepted |
| 2 | Trends in supply and demand of medicines <br> - All members commented that over the last two weeks there have been no abnormal demand or signs of concern regarding potential stockpiling behaviour. | All members to watch ordering behavior closely and report back into the group immediately if they detect any areas of concern |
| 3 | - Specific medicines at risk - NEW <br> - No new medicines noted as being at risk. | Noted |
| 4 | Specific medicines at risk - EXISTING |  |




NPSA fortnightly operational update table for fortnight ending October 92020

| Medicine/Pharmacy <br> Product | Description of supply <br> chain challenge | Proposed Solution <br> (arising from <br> Applicants' <br> discussions) | Update on progress of <br> implementation/benefits <br> to the public | Interim <br> Authorisations which <br> the collaborative <br> conduct was <br> pursuant to |
| :--- | :--- | :--- | :--- | :--- |
|  |  |  |  | NPSA application for <br> Authorisation |
|  |  |  |  |  |








September 2020

## TGA and NPSA Medicine Shortages Wholesaler Data Reporting <br> Protocol

$\square$





Australian Government<br>Department of Health<br>Therapeutic Goods Administration



# Australian Government 

Department of Health
Therapeutic Goods Administration


# Australian Government 

Department of Health
Therapeutic Goods Administration


Department of Health
Therapeutic Goods Administration




## NPSA Medicines Shortages CSOD Supply Restriction under COVID-19 Working Group

## Minutes 16



| ITEM | DISCUSSION AREA | ACTION AGREED |
| :---: | :---: | :---: |
| 1 | Welcome - <br> - meeting purpose and conduct as per ACCC temporary authorisation was discussed and agreed. <br> - Minutes from September 29, 2020 meeting accepted | Noted <br> Minutes Accepted |
| 2 | Trends in supply and demand of medicines <br> - All members commented that over the last four weeks there has been no abnormal demand or signs of concern regarding potential stockpiling behaviour | All members to watch ordering behavior closely and report back into the group immediately if they detect any areas of concern |
| 3 | - Specific medicines at risk - NEW <br> - No new medicines noted as being at risk | Noted |
| 4 | Specific medicines at risk - EXISTING |  |




